1. Home
  2. CPSS vs DRUG Comparison

CPSS vs DRUG Comparison

Compare CPSS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPSS
  • DRUG
  • Stock Information
  • Founded
  • CPSS 1991
  • DRUG 2019
  • Country
  • CPSS United States
  • DRUG United States
  • Employees
  • CPSS N/A
  • DRUG N/A
  • Industry
  • CPSS Finance: Consumer Services
  • DRUG Pharmaceuticals and Biotechnology
  • Sector
  • CPSS Finance
  • DRUG Health Care
  • Exchange
  • CPSS Nasdaq
  • DRUG Nasdaq
  • Market Cap
  • CPSS 193.8M
  • DRUG 199.7M
  • IPO Year
  • CPSS 1992
  • DRUG N/A
  • Fundamental
  • Price
  • CPSS $9.77
  • DRUG $25.41
  • Analyst Decision
  • CPSS
  • DRUG Strong Buy
  • Analyst Count
  • CPSS 0
  • DRUG 7
  • Target Price
  • CPSS N/A
  • DRUG $83.25
  • AVG Volume (30 Days)
  • CPSS 23.3K
  • DRUG 60.5K
  • Earning Date
  • CPSS 07-29-2025
  • DRUG 08-13-2025
  • Dividend Yield
  • CPSS N/A
  • DRUG N/A
  • EPS Growth
  • CPSS N/A
  • DRUG N/A
  • EPS
  • CPSS 0.79
  • DRUG N/A
  • Revenue
  • CPSS $188,776,000.00
  • DRUG N/A
  • Revenue This Year
  • CPSS $146.82
  • DRUG N/A
  • Revenue Next Year
  • CPSS $18.24
  • DRUG N/A
  • P/E Ratio
  • CPSS $12.32
  • DRUG N/A
  • Revenue Growth
  • CPSS N/A
  • DRUG N/A
  • 52 Week Low
  • CPSS $7.99
  • DRUG $0.93
  • 52 Week High
  • CPSS $12.73
  • DRUG $79.02
  • Technical
  • Relative Strength Index (RSI)
  • CPSS 58.96
  • DRUG 43.34
  • Support Level
  • CPSS $9.79
  • DRUG $26.09
  • Resistance Level
  • CPSS $10.18
  • DRUG $27.50
  • Average True Range (ATR)
  • CPSS 0.29
  • DRUG 1.95
  • MACD
  • CPSS -0.02
  • DRUG 0.12
  • Stochastic Oscillator
  • CPSS 74.14
  • DRUG 44.62

About CPSS Consumer Portfolio Services Inc.

Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: